Abstract: A dental implant system comprising a fixture (301; 401; 501) for implantation in bone tissue (312, 314; 512, 514) of the maxilla or mandible by displacement thereof in a forward direction, the fixture having a forward end, a rearward end (330; 430; 530), and an outer surface (305; 405; 505) which extends between the forward and rearward ends and which forwardly of a predetermined position (307; 407; 507) on the outer surface is adapted for interlocking with bone tissue of the maxilla or mandible; and a superstructure (402) for mounting on the fixture, the superstructure having a forward end for interfacing with the rearward end of the fixture, the forward end of the superstructure and the rearward end of the fixture each presenting interfacing surfaces for interfacing with one another.

Abstract: The invention relates to a composition comprising of a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in the form of the free base, pharmaceutically acceptable salts and/or solvates thereof, and a second component (b) which is a monoamine oxidase (MAO) inhibitor in the form of the free base, pharmaceutically acceptable salts and/or solvates thereof, the preparation thereof, pharmaceutical formulations containing said composition, a kit containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition.

Abstract: The present invention relates to benzimidazole derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Abstract: The invention provides a process for preparing essentially crystalline particles containing a substance in solvated form, by dissolving the substance in a first solvent, introducing the solution and a supercritical or subcritical fluid into an apparatus, wherein the fluid contains an anti-solvent and a second solvent, which is water. Preferably, the anti-solvent is carbon dioxide which is totally saturated with the second solvent, which is water. The invention further provides formulations comprising particles produced according to the present process containing one or more pharmacologically active substances and one or more pharmaceu-tically acceptable excipients, use of said formulations in the treatment of an allergic and/or inflammatory condition of the nose or lungs and methods for treatment of such conditions.

Abstract: The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.

Abstract: The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.

Abstract: The invention is directed to run-free, wholly elastic fabrics. The knitted fabrics of the invention are produced on a warp knitting machine comprising knitting elements including a needle bar and at least two guide bars for stitching in varying proximity to the needle bar. The guide bars are threaded with an elastic yarn. The elastic yarn is knitted together by moving the knitting elements to produce a series of stitches forming the knitted fabric. Advantageously, the method of the invention makes it possible to produce wholly elastic fabrics with high run-resistant properties without knitting the elastic yarn with natural or other synthetic fibers. The invention also relates to wholly elastic warp knitted fabrics comprising an inlaid yarn. The inlay may be an elastomeric or non-elastomeric warp yarn, weft insertion yarn or combination thereof.

Abstract: The present invention provides a method and apparatus for use in elevator systems for assigning new hall calls to one of a plurality of available elevator cars. According to the invention, a call cost is calculated for each car for accepting the new hall call. The call cost is a function of the estimated time to the desired destination of the passenger requesting the new hall call and of the delay that other passengers who are using the elevator car will experience. In one embodiment, a destination is inferred for the passenger requesting the new hall call. In another embodiment, the passenger requesting the hall call may input a desired destination at the time the hall call request is made. The elevator system of the present invention allows for use of both standard up/down hall call entry devices and destination entry devices that allow a particular destination to be entered by a passenger at the time a hall call is requested.

Abstract: An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, one of the single enantiomers of omeprazole and an alkaline salt of one of the single enantiomers of omeprazole, wherein the formulation comprises a core material that comprises the active ingredient and optionally an alkaline reacting compound, the active ingredient is in admixture with a pharmaceutically acceptable excipient, such as for instance a binding agent, and on said core material a separating layer and an enteric coating layer. A hydroxypropyl cellulose (HPC) with a specific cloud point is used in the manufacture of the claimed pharmaceutical formulations. Furthermore, the application describes the processes for their preparation and the use of the claimed formulations in medicine.

Abstract: A jacket-assembly is sealed to a hydraulic elevator jack to protect the jack from corrosion. The jacket-assembly is preferably manufactured from a non-galvanic, non-corrosive material, such as high density polyethylene tubing. The jacket may be manufactured from any non-galvanic, non-corrosive material that is strong enough and flexible enough to be factory-installed on the jack. The jacket is preferably hermetically sealed to the jack. The jacket-assembly may contain a bulkhead mounted on the hydraulic elevator jack having an O-ring groove. An O-ring can be used to effect a hermetic seal between the bulkhead and the jacket. The bulkhead may be mounted on the jack with any conventional means, such as a weld. In one embodiment, a moisture sensor may be placed inside the jacket.

Abstract: Use of one or more saccharides, for example one or more non-toxic mono-, di-, tri-, oligo- or polysaccharides, in the manufacture of a biocompatible glue for adhering a first structure to a surface of a second structure. The biocompatible glue can be adapted to act as a temporary glue. In this case the glue may be used to enable a medical structure to be transferred from a medical instrument onto the surface of a structure of a human or animal body, for example as in the transfer of a buffer material from the fork of a surgical stapler to a diseased lung after one or more rows of staples have been fired through the buffer material into the lung during lung volume reduction surgery for treating emphysema. The biocompatible glue can also to advantage be used to adhere or secure medical structures to a structure of a human or animal body direct, such as in the case of a patch being applied to the skin of a mammal.

Abstract: A fluid diffuser and a method for diffusing fluid are provided. In one preferred embodiment, the diffuser comprises a frame adapted to be connected to the end of fluid supply duct. Mounted within the frame is a pore-containing web. The web redirects fluid passing through the pores by changing the direction of the fluid upon exiting the web. Prescribed portions of the web can be blocked to expel fluid preferentially in one direction and expel fluid less in other directions. Other means for controlling the direction and flow of fluid upon exiting the web are provided, including changing the angle of fluid supply to the web, and placing a vane at the entrance to the web.

Abstract: Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as relapse preventing therapy for Crohn's colitis in its chronic phase and Crohn's disease in the small intestine.

Abstract: A blended solid composition is provided containing a fibrillatable microparticulate PTFE polymer in an unfibrillated state and at least one elastomeric and/or fluoroplastic component. The composition is useful in making microfiber-reinforced solid compositions and articles produced therefrom.

Abstract: Applicants have developed a process for purifying an ampicillin pro-drug ester, e.g., bacampicillin, or an acid addition salt thereof of formula I. The process comprises a step wherein a crude solution of the pro-drug ester is subjected to an evaporation which is controlled by the evaporation rate of the organic solvent such that a continuous operation is accomplished for the crystallization of the desired purified pro-drug ester or salt thereof. Said crystallization is preferably preceded by an aqueous phase extraction and/or an organic phase extraction, both preferably also being performed continuously.

Abstract: New piperidinyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having the formula wherein X is N or CH; Y is NR2CH2, CH2—NR2, NR2—CO, CO—NR2 or NR2SO2; R1 is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, where aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; as (R)-enantiomer, (S)-enantiomer or a racemate in the form of the free base or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical formulation containing the compounds, use of the compounds in the treatment of 5-hydroxytryptamine mediated disorders, processes for the preparation of the compounds and intermediates for the preparation of the compounds.